| Business Summary | | SkyePharma
plc
is
a
public
limited
company
that
develops
methods
for
delivering
drugs
in
the
human
body
based
on
five
technology
platforms
in
the
following
areas:
oral,
injectable,
inhalation,
topical
and
nano-particulate.
A
significant
part
of
the
Company's
business
is
developing
applications
of
its
Geomatrix
technologies.
Geomatrix
is
a
range
of
technologies
by
which
drugs
taken
orally
in
tablet
form
are
formulated
so
as
to
control
the
amount,
timing
and
location
of
the
release
of
the
drug
in
the
body. | More
from
Market Guide: Expanded
Business Description |
| Financial Summary | | SkyePharma
plc
develops
methods
for
delivering
drugs
in
the
human
body.
The
Company,
through
its
Geomatrix
technologies,
focuses
on
the
amount,
timing
and
location
of
the
release
of
the
drug
in
the
body.
For
the
fiscal
year
ended
12/00,
revenues
rose
37%
to
L24.3
million.
Net
loss
under
U.S.
GAAP
adjustment
rose
3%
to
L29.2
million.
Results
reflect
higher
contract
R&D
and
manufacturing
revenues,
offset
by
higher
R
and
D
expenses,
and
goodwill
amortization. | More
from
Market Guide: Significant
Developments |
| | | | FY1999 Pay | |
| Ian Gowrie-Smith, 52 Exec.
Chairman | $475K | Michael Ashton, 54 CEO,
Director | 449K | Donald Nicholson, 42 Director
and Fin. Director | 216K | Suzanne McLean, 46 Sec.
and International Legal Counsel | 39K | Dollar amounts are as of 31-Dec-1999 and compensation values are for the fiscal year ending on that date; "Pay" is salary, bonuses, etc.. |
| More
from
Market Guide on Officers & Directors: Expanded
List, Bios,
Compensation,
Options
|
|